Elesclomol: Apoptosis inducer inducer of oxidative stress HSP70 inducer oncolytic

Drugs of the Future

Volumn 33, Issue 4, 2008, Pages 310-315

  Revill, P ^a   Mealy, N ^a   Serradell, N ^a   Rosa, E ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; ELESCLOMOL; GEMCITABINE; PACLITAXEL; RITUXIMAB; STA 4783;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; CANDIDIASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; CYTOTOXICITY; DEHYDRATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; HYPESTHESIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MITOCHONDRION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; RASH; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; TUMOR XENOGRAFT; VOMITING;

EID: 45949087683     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.04.1192992     Document Type: Article

References (31)

1. Chen, S., Sun, L., Ono, M., Koya, K., Xia, Z.-Q. (SBR Pharmaceuticals Corp.). Synthesis of taxol enhancers. US 2003069225, US 6825235, WO 03006429.
2. Koya, K., Sun, L., Ono, M., Tatsuta, N., Wu, Y., Chen, S. (Synta Pharmaceuticals Corp.). Taxol enhancer compounds. EP 1406869, EP 1731148, JP 2004534848, US 2003119914, WO 03006430.
3. Kostik, E., Vaghefi, F., Liang, G. et al. (Synta Pharmaceuticals Corp.). EP 1781604, WO 2006009940.
4. Tarhini, A.A., Agarwala, S.S. Cutaneous melanoma: Available therapy for metastatic disease. Dermatol Ther 2006, 19(1): 19-25.
5. Thompson, J.F., Scolyer, R.A., Kefford, R.F. Cutaneous melanoma. Lancet 2005, 365(9460): 687-701.
6. Fruehauf, J.P., Meyskens, F.L. Jr. Reactive oxygen species: A breath of life or death? Clin Cancer Res 2007, 13(3): 789-94.
7. Schumacker, P.T. Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 2006, 10(3): 175-6.
8. Pelicano, H., Carney, D., Huang, P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004, 7(2): 97-110.
9. Overview of elesclomol (formerly STA-4783) in metastatic melanoma. Synta Pharmaceuticals Presentation, November 2007.
10. Kirshner, J., Du, Z., Kepros, J. et al. The taxane-enhancer STA-4783 induces Hsp70 expression and apoptosis via an oxidative stress mechanism. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 14107.
11. Kirshner, J., Du, Z., Kepros, J. et al. The novel small molecule elesclomol (formerly STA-4783) induces apoptosis in cancer cells through induction of oxidative stress. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 22-26, San Francisco) 2007, Abst B274.
12. Synta presents results for STA-4783 in metastatic melanoma showing improvement in overall survival. Synta Pharmaceuticals Press Release, June 5, 2007.
13. Synta and GlaxoSmithKline announce elesclomol granted orphan drug designation by the FDA. Synta Pharmaceuticals Press Release, January 28, 2008.
14. Koya, K., Sun, L., Chen, S. et al. STA-4783, a novel HSP70 inducer, enhances the anti-cancer activity of paclitaxel without increasing toxicity in preclinical studies. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 1504.
15. Foley, K.P., Allen, I., Bertin, J. et al. The oxidative stress inducer elesclomol (formerly STA-4783) enhances the in vivo efficacy of multiple anti-cancer therapies in mouse tumor models. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 22-26, San Francisco) 2007, Abst A290.
16. Tatsuta, N., Liang, G., Wang, Q. et al. A novel HSP-70 inducer STA-4783 enhances the anticancer activity of paclitaxel without altering paclitaxel pharmacokinetics. Preclinical pharmacokinetics, distribution and excretion study of STA-4783. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 2125.
17. Berkenblit, A., Eder, J.P. Jr., Ryan, D.P. et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 2007, 13(2): 584-90.
18. Berkenblit, A., Supko, J., Ryan, D.P. et al. STA-4783 in combination with paclitaxel induces heat shock protein 70 (hsp70) in a phase I trial. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 2011.
19. Zhou, D., McKeon, M.E., Dahl, T. et al. Pre-clinical toxicology evaluation of STA-4783 alone or combination with paclitaxel in rats, mice, and dogs. Proc Am Assoc Cancer Res (AACR) 2004, 45: Abst 2112.
20. STA-4783 in combination with paclitaxel and carboplatin for the treatment of chemotherapy naive patients with stage IIIB/IV non small cell lung cancer (NSCLC) (NCT00088088). ClinicalTrials.gov Web site, March 13, 2008.
21. Jacobs, M., Weber, R., Hainsworth, J. et al. A phase 1/2 study of STA-4783 in combination with paclitaxel and carboplatin in chemo-naive advanced non-small cell lung cancer (NSCLC). 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 7106.
22. Hainsworth, J., Weber, R., Jacobs, M. et al. Results of a phase 2 study of STA-4783 in combination with paclitaxel and carboplatin in patients with previously untreated advanced non-small cell lung cancer (NSCLC). 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst B112.
23. Sherman, M.L., Ryan, C., Blackstein, M. et al. Phase 1/2 study of STA-4783, a novel heat shock protein 70 (hsp70) inducer, in combination with paclitaxel in patients with soft tissue sarcomas (STS). 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 9069.
24. Baker, L.H., Ryan, C., Agarwala, S. et al. Preliminary results of a phase 2 study of the novel heat shock protein 70 (hsp70) inducer, STA-4783, in combination with paclitaxel in patients with soft tissue sarcomas. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst B108.
25. STA-4783/paclitaxel or paclitaxel alone in melanoma (NCT00084214). ClinicalTrials.gov Web site, March 13, 2008.
26. Powderly, J., Khan, K., Richards, J. et al. A 2-stage controlled phase 1/2 study of STA-4783 in combination with paclitaxel in patients with advanced metastatic melanoma. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 7561.
27. Powderly, J., Khan, K., Urba, W. et al. A 2-stage, randomized, blinded phase 2 study of STA-4783 in combination with paclitaxel in patients with advanced metastatic melanoma. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C95.
28. Williams, A., Gonzalez, R., Lawson, D. et al. Oxidative stress induction: An old idea whose time has come. MOA and clinical correlates of the oxidative stress inducer STA4783. Eur J Cancer - Suppl [14th Eur Cancer Conf (ECCO) (Sept 23-27, Barcelona) 2007] 2007, 5(4): Abst 7002.
29. O'Day, S., Gonzalez, R., Lawson, D. et al. Subgroup analysis of efficacy and safety analysis of a randomized, double-blind-ed controlled phase 2 study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. 1st World Meet Interdiscip Melanoma Skin Cancer Cent (Sept 5-8, Barcelona) 2007, Abst S2.
30. O'Day, S., Gonzalez, R., Lawson, D. et al. Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 8528.
31. STA-4783 with paclitaxel versus paclitaxel alone in melanoma (NCT00522834). ClinicalTrials.gov Web site, March 13, 2008.